Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

4.230 +0.290 (+7.36%)
Streaming Delayed Price Updated: 11:50 AM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,839
Open 3.930
Bid (Size) 4.160 (100)
Ask (Size) 4.250 (1,500)
Prev. Close 3.940
Today's Range 3.875 - 4.270
52wk Range 3.680 - 59.40
Shares Outstanding 11,523,716
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
From Aptevo Therapeutics
Via ACCESS Newswire
News headline image
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-55.0%
-55.0%
1 Month
-11.5%
-11.5%
3 Month
-10.8%
-10.8%
6 Month
-52.8%
-52.8%
1 Year
-92.0%
-92.0%

More News

Read More
News headline image
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Via ACCESS Newswire
News headline image
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Via ACCESS Newswire
News headline image
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
Via NewMediaWire
News headline image
Aptevo Provides State of the Business Report and 2025 Financial Results
Via ACCESS Newswire
News headline image
Aptevo to Participate in March 2026 Conferences
Via ACCESS Newswire
Gapping stocks in Tuesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Via ACCESS Newswire
News headline image
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Via ACCESS Newswire
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Via ACCESS Newswire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Top movers in Friday's session ↗
Via Chartmill
News headline image
Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval ↗
Via Stocktwits
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
What's Going On With Aptevo Therapeutics Stock Today? ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Via ACCESS Newswire
News headline image
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Via ACCESS Newswire
News headline image
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire

Frequently Asked Questions

Is Aptevo Therapeutics Inc. - Common Stock publicly traded?
Yes, Aptevo Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Aptevo Therapeutics Inc. - Common Stock trade on?
Aptevo Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aptevo Therapeutics Inc. - Common Stock?
The ticker symbol for Aptevo Therapeutics Inc. - Common Stock is APVO on the Nasdaq Stock Market
What is the current price of Aptevo Therapeutics Inc. - Common Stock?
The current price of Aptevo Therapeutics Inc. - Common Stock is 4.230
When was Aptevo Therapeutics Inc. - Common Stock last traded?
The last trade of Aptevo Therapeutics Inc. - Common Stock was at 07/13/26 11:50 AM ET
What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 48.75M
How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
Aptevo Therapeutics Inc. - Common Stock has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.